<div id="readability-page-1"><p>Eli Lilly and Company (NYSE:LLY - Get Free Report)'s share price traded down 0.6% on Wednesday . The stock traded as low as $939.17 and last traded at $944.52. 1,103,435 shares were traded during trading, a decline of 64% from the average session volume of 3,092,851 shares. The stock had previously closed at $949.97.</p><div><p><span></span><span>Get <strong>Eli Lilly and Company</strong> alerts:</span></p></div><h2>Analyst Ratings Changes</h2><ul><li>Merck's Stock Dip Offers a Buying Opportunity: Here’s Why</li></ul><p>Several analysts have weighed in on the company. Guggenheim boosted their price target on Eli Lilly and Company from $884.00 to $1,030.00 and gave the company a &#34;buy&#34; rating in a research note on Friday, August 16th. Argus boosted their price objective on Eli Lilly and Company from $770.00 to $840.00 and gave the company a &#34;buy&#34; rating in a report on Tuesday, May 14th. Jefferies Financial Group boosted their price objective on Eli Lilly and Company from $994.00 to $1,015.00 and gave the company a &#34;buy&#34; rating in a report on Monday, June 24th. Deutsche Bank Aktiengesellschaft raised Eli Lilly and Company from a &#34;hold&#34; rating to a &#34;buy&#34; rating and boosted their price objective for the company from $725.00 to $1,025.00 in a report on Monday, August 12th. Finally, Truist Financial reissued a &#34;buy&#34; rating and issued a $1,000.00 price objective (up previously from $892.00) on shares of Eli Lilly and Company in a report on Tuesday, June 25th. Two research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $956.88.</p><p><b>View Our Latest Analysis on Eli Lilly and Company</b></p><h2>Eli Lilly and Company Trading Up 0.2 %</h2><ul><li>MarketBeat Week in Review – 8/5 - 8/9</li></ul><p>The company has a 50 day simple moving average of $881.72 and a 200 day simple moving average of $810.11. The company has a debt-to-equity ratio of 1.90, a quick ratio of 1.03 and a current ratio of 1.35. The company has a market capitalization of $905.04 billion, a PE ratio of 139.10, a price-to-earnings-growth ratio of 1.81 and a beta of 0.41. </p><h2>Eli Lilly and Company Dividend Announcement</h2><p>The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Thursday, August 15th will be paid a dividend of $1.30 per share. The ex-dividend date is Thursday, August 15th. This represents a $5.20 annualized dividend and a yield of 0.55%. Eli Lilly and Company's dividend payout ratio (DPR) is currently 76.58%. </p><h2>Insiders Place Their Bets</h2><ul><li>Novo Nordisk's Shares Go on a Rollercoaster Ride After Earnings</li></ul><p>In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 210,000 shares of the business's stock in a transaction that occurred on Wednesday, July 10th. The stock was sold at an average price of $939.82, for a total transaction of $197,362,200.00. Following the completion of the sale, the insider now directly owns 96,943,810 shares in the company, valued at approximately $91,109,731,514.20. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other news, major shareholder Lilly Endowment Inc sold 210,000 shares of the company's stock in a transaction that occurred on Wednesday, July 10th. The stock was sold at an average price of $939.82, for a total value of $197,362,200.00. Following the completion of the sale, the insider now directly owns 96,943,810 shares in the company, valued at $91,109,731,514.20. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through the SEC website. Also, EVP Johna Norton sold 7,056 shares of the company's stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $819.38, for a total value of $5,781,545.28. Following the completion of the sale, the executive vice president now owns 25,428 shares of the company's stock, valued at $20,835,194.64. The disclosure for this sale can be found here. In the last three months, insiders sold 1,214,704 shares of company stock worth $1,066,841,316. Corporate insiders own 0.13% of the company's stock. </p><h2>Institutional Investors Weigh In On Eli Lilly and Company</h2><p>A number of large investors have recently made changes to their positions in the stock. Pathway Financial Advisers LLC grew its position in Eli Lilly and Company by 4.2% in the second quarter. Pathway Financial Advisers LLC now owns 1,101 shares of the company's stock worth $982,000 after acquiring an additional 44 shares during the period. HWG Holdings LP purchased a new position in Eli Lilly and Company in the second quarter worth approximately $14,902,000. EP Wealth Advisors LLC grew its position in Eli Lilly and Company by 0.4% in the second quarter. EP Wealth Advisors LLC now owns 31,326 shares of the company's stock worth $28,362,000 after acquiring an additional 130 shares during the period. Kimelman &amp; Baird LLC purchased a new position in Eli Lilly and Company in the second quarter worth approximately $34,368,000. Finally, Gateway Wealth Partners LLC grew its position in Eli Lilly and Company by 3.2% in the second quarter. Gateway Wealth Partners LLC now owns 799 shares of the company's stock worth $723,000 after acquiring an additional 25 shares during the period. 82.53% of the stock is currently owned by hedge funds and other institutional investors. </p><h2>About Eli Lilly and Company</h2> (Get Free Report)<p>Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Eli Lilly and Company</li><li>3 Natural Gas Stocks That Offer Great Dividend Yields</li><li>Target Hits the Mark: Q2 Earnings Exceed Expectations</li><li>What is a Low P/E Ratio and What Does it Tell Investors?</li><li>Is Tesla’s Rebound Just Starting? Why You Should Consider Buying</li><li>What Makes a Stock a Good Dividend Stock?</li><li>Stanley Druckenmiller's Latest Bet: MELI—Should You Follow Suit?</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><p>→ “Generational buying opportunity” - Blackstone <span><span>(From Porter &amp; Company)</span> <span>(Ad)</span></span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MjA4?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MjA4"/></p><h2>Should you invest $1,000 in Eli Lilly and Company right now?</h2><p>Before you consider Eli Lilly and Company, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.</p><p>While Eli Lilly and Company currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p> </div>

<p>Eli Lilly and Company (NYSE:LLY) shares traded down 0.6% to $487.52 on Wednesday, with a 64% decline in trading volume compared to average. Analysts generally hold a positive outlook with several upgrades in price targets; the average target is $651.88, indicating a "Moderate Buy" consensus. The company recently announced a quarterly dividend of $0.30 per share set for September 10. Insider activity includes significant share sales by major shareholder Lilly Endowment Inc., which sold 210,000 shares at an average price of $480.82.</p>

Eli Lilly and Company (NYSE:LLY) Trading Down 0.6%